NEW ORLEANS — Aspirin therapy is commonly used for primary prevention of cardiovascular events in persons with type 2 diabetes, but a Japanese study of 2,539 subjects found no statistically significant reduction in the primary end point of total atherosclerotic events, except in patients aged at least 65 years.
PREVIEW